CDX2 and colorectal carcinoma: In the next step, we wanted to know if this general observation holds true when specific subcohorts of CRCs are investigated, which was the case when we analysed CRCs in UICC Stage II and III, where the prognostic power of CDX2 expression was also considerably lower compared to CRC subtypes, WHO grade and tumour budding.